In addition to the active ingredient, each capsule contains croscarmellose sodium, povidone K30, pregelatinized starch, sodium stearyl fumarate and talc.
Antiflu-Des (Antiflu-Des phosphate), an inhibitor of influenza neuraminidase (NAI), is available as:
- Capsules containing 30 mg, 45 mg or 75 mg of Antiflu-Despara oral use, in the form of Antiflu-Des phosphate, and a powder for oral suspension, which when constituted with water as indicated contains 6 mg per ml of base of Antiflu-Des.
What are the possible side effects of Antiflu-Des?
Stop using Antiflu-Des and seek emergency medical help if you have any of these symptoms of an allergic reaction:
- Difficult breathing
- Swelling of your face
- Tongue or throat
- Red skin rash
- Blisters or peeling
Some people using Antiflu-Des have had rare side effects of:
- Sudden confusion
- Unusual behavior or self-injury
- These symptoms have occurred more frequently in children.
- It is not known if Antiflu-Des was the exact cause of these symptoms.
Indications and doses
Treatment of influenza
Antiflu-Des is indicated for the treatment of acute and uncomplicated diseases caused by influenza A and B in patients 2 weeks of age or older who have had symptoms for no longer than 48 hours.
Prophylaxis of influenza
Antiflu-Des is indicated for the prophylaxis of influenza A and B in patients 1 year and older.
Limitations of use
Antiflu-Des is not a substitute for early influenza vaccination annually as recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
Influenza viruses change over time. The appearance of resistance substitutions could decrease the efficacy of the drug.
Other factors (for example, changes in viral virulence ) may also decrease the clinical benefit of antiviral drugs.
Prescribers should consider the information available on patterns of susceptibility to influenza medications and the effects of treatment.
Administer Antiflu-Des for the treatment of influenza in patients of 2 weeks or more (see Recommended dose for the treatment of influenza) or for the prophylaxis of influenza in patients 1 year and older using:
- Oral suspension (supplied as a powder): This is the preferred formulation (6 mg per ml) for patients who can not swallow the capsules. Before use, the supplied Antiflu-Des powder should be constituted with water by the pharmacist to produce the oral suspension.
Capsules and oral suspension can be taken with or without food; however, tolerability can be improved if Antiflu-Des is taken with food.
Antiflu-Des capsules can be opened and mixed with sweetened liquids such as normal or unsweetened chocolate syrup, corn syrup, caramel topping or brown sugar (dissolved in water).
Dosage of treatment
For Treatment Against Influence with Antiflu-Des within 48 hours of flu symptoms for adults and adolescents (13 years of age and older):
- 75 mg twice a day (one 75 mg capsule or 12.5 ml oral suspension twice a day) for 5 days.
- Pediatric patients (2 weeks of age up to 12 years of age).
The following serious adverse reactions are discussed below and elsewhere:
- Severe skin reactions and hypersensitivity reactions.
- Neuropsychiatric events.
- Swelling of the face or tongue
- Allergy, anaphylaxis / anaphylactoid reactions.
- Skin and subcutaneous tissue disorders: Skin rash, dermatitis, urticaria, eczema, toxic epidermal necrolysis.
- Stevens-Johnson syndrome.
- Erythema multiforme.
- Gastrointestinal disorders: Gastrointestinal bleeding, hemorrhagic colitis.
- Cardiac disorders: Arrhythmia.
- Hepatobiliary disorders: Hepatitis, abnormal liver functional tests.
- Nervous system disorders: Convulsions.
- Metabolism and nutritional disorders: Aggravation of diabetes.
- Psychiatric diseases: Abnormal behavior, delirium, including symptoms such as hallucinations, agitation, anxiety, altered level of consciousness, confusion, nightmares, delusions.
Do not administer if you use:
- Antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine or warfarin.
Influenza can be associated with a variety of neurological and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, which in some cases result in fatal outcomes.
These events can occur in the setting of encephalitis or encephalopathy, but they can occur without a serious, obvious illness.
Closely monitor patients treated with Antiflu-Des with influenza for signs of abnormal behavior.
If neuropsychiatric symptoms occur, evaluate the risks and benefits of continuing Antiflu-Des for each patient.
Risk of bacterial infections
There is no evidence of the efficacy of Antiflu-Des in any disease caused by other pathogens other than influenza viruses. Severe bacterial infections may begin with flu-like symptoms or may coexist or present as complications during the course of influenza.
Antiflu-Des has not been proven to avoid such complications. Prescribers should be alert to the possibility of secondary bacterial infections and treat them accordingly.
Maternal and / or embryonic / fetal risk associated with diseases is at increased risk of serious complications of influenza, which can cause adverse pregnancies and / or fetal outcomes including maternal death, stillbirths, congenital defects, premature births, low birth weight at birth and small for gestational age.